Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene
Selpercatinib (LOXO-292) is a targeted therapy that works by inhibiting the activity of abnormal RET proteins. The drug is an oral therapy that patients take as a pill.
Cancer care